1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
TC Biopharm (Holdings) Plc

TC Biopharm (Holdings) Plc

TCBPW
TC Biopharm (Holdings) PlcUS flagNASDAQ Global Select
0.01
USD
- -
- -
1,282.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
3
2
2
4
- -
Operating Margin (%)
-193.78
-320.36
-367.96
-314.32
- -
Depreciation Expense
1
1
1
1
1
Net Income, GAAP
-6
-5
-14
-1
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-177.07
-275.84
-686.12
-34.17
- -
Working Capital
- -
-2
-17
-2
1
LT Debt
3
3
2
2
1
Total Equity
-3
-3
-17
- -
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
710.6%
Free Cash Flow
- -
- -
-31.32%
Net Income, GAAP
- -
- -
349.68%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
4
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Bryan Leland Kobel
Full Time Employees
41
Sector
Healthcare
Industry
Biotechnology
Address
Maxim 1 Motherwell United Kingdom ML1 4WR
CIK
0001872812
Website
tcbiopharm.com
Similar Companies
Xeris Biopharma Holdings, Inc. (0A8E.L)
Yulong Eco-Materials Limited (YECO)
Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
Matinas BioPharma Holdings, Inc. (MTNB)
GenVec, Inc. (GNVC)
Arch Biopartners Inc. (ACHFF)
Business
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company that develops platform allogeneic gamma delta T cell therapies and CAR-T cell therapies for cancer and infectious diseases; its lead product candidate, OmnImmune (TCB-002), is an unmodified gamma delta T cell therapy in Phase 2/3 trials for acute myeloid leukemia; ImmuniStim targets viral infections and solid tumors; and the company advances preclinical CAR-modified gamma delta T cells for hematological and solid tumor indications. Founded in 2013 and headquartered in Motherwell, United Kingdom, TC Biopharm operates primarily from its GMP manufacturing facility in Scotland, with clinical activities spanning the United States, United Kingdom, and Europe, serving patients with relapsed/refractory cancers and infectious diseases through its integrated model of preclinical development, manufacturing, and clinical translation. Recent developments include signing non-binding letters of intent in 2025 for acquisitions of an ophthalmic pharmaceutical company with an FDA-approved glaucoma eye drop and other cell therapy assets to diversify beyond oncology; a strategic partnership with CareDx to advance AML therapy trials; preclinical proof-of-concept initiation for Mpox treatment; and a collaboration with a leading UK university on AI for donor screening in allogeneic therapies, amid a cash bid from CytoMed for relevant assets following TC Biopharm Limited's administration in October 2025.